Markus Ritter

Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

PloS one

Cancers

Methods and protocols

Journal of clinical medicine

Paracelsus Medical University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Paracelsus Medical University

Austria

Director and Chairman :: Institute for Physiology and Pathophysiology

University of Innsbruck

Austria

Deputy Director :: Institute of Physiology and Balneology

University of Innsbruck

Austria

Ass. Prof. :: Institute of Physiology and Balneology

University of Innsbruck

Austria

Assistant Doctor :: Hospital for Internal Medicine

Publications

Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter, Heidemarie Dobias, Marlena Beyreis, Daniel Neureiter, Christian Mayr
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one 19 (4) (2024)
Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter, Heidemarie Dobias, Marlena Beyreis, Daniel Neureiter, Christian Mayr
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one 19 (4) (2024)
Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter, Heidemarie Dobias, Marlena Beyreis, Daniel Neureiter, Christian Mayr
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one 19 (4) (2024)
Christian Josef Wiedermann, Pasqualina Marino, Antje van der Zee-Neuen, Isabella Mastrobuono, Angelika Mahlknecht, Verena Barbieri, Sonja Wildburger, Julia Fuchs, Alessandra Capici, Giuliano Piccoliori, Adolf Engl, Nina Østerås, Markus Ritter
Patient-Reported Quality of Care for Osteoarthritis in General Practice in South Tyrol, Italy: Protocol for Translation, Validation and Assessment of the OsteoArthritis Quality Indicator Questionnaire (OA-QI). Methods and protocols 6 (2) (2023)
Christian Mayr, Tobias Kiesslich, Dino Bekric, Marlena Beyreis, Michael Kittl, Celina Ablinger, Elen Neureiter, Martin Pichler, Felix Prinz, Markus Ritter, Daniel Neureiter, Martin Jakab, Heidemarie Dobias
Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells. PloS one 18 (6) (2023)
Dino Bekric, Daniel Neureiter, Celina Ablinger, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Martin Jakab, Johannes Bischof, Ulrich Koller, Tobias Kiesslich, Christian Mayr
Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers 15 (5) (2023)
Dino Bekric, Daniel Neureiter, Celina Ablinger, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Martin Jakab, Johannes Bischof, Ulrich Koller, Tobias Kiesslich, Christian Mayr
Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers 15 (5) (2023)
Christian Mayr, Tobias Kiesslich, Dino Bekric, Marlena Beyreis, Michael Kittl, Celina Ablinger, Elen Neureiter, Martin Pichler, Felix Prinz, Markus Ritter, Daniel Neureiter, Martin Jakab, Heidemarie Dobias
Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells. PloS one 18 (6) (2023)
Christian Mayr, Tobias Kiesslich, Dino Bekric, Marlena Beyreis, Michael Kittl, Celina Ablinger, Elen Neureiter, Martin Pichler, Felix Prinz, Markus Ritter, Daniel Neureiter, Martin Jakab, Heidemarie Dobias
Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells. PloS one 18 (6) (2023)
Dino Bekric, Matthias Ocker, Christian Mayr, Sebastian Stinzing, Markus Ritter, Tobias Kiesslich, Daniel Neureiter
Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers 14 (7) (2022)
Christian Mayr, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jäger, Bettina Neumayer, Paul Winkelmann, Eckhard Klieser, Daniel Neureiter
HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers 13 (15) (2021)
Dino Bekric, Daniel Neureiter, Markus Ritter, Martin Jakab, Martin Gaisberger, Martin Pichler, Tobias Kiesslich, Christian Mayr
Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review. Journal of clinical medicine 9 (4) (2020)

Markus Ritter.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Markus Ritter